Patricia Araceli Quispe

Dr. Patricia Araceli Quispe


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
LHLeandro Martinez Heredia
Leandro Martinez Heredia
PQPatricia Araceli Quispe
Patricia Araceli Quispe
JFJulián Fernández
Julián Fernández
Martin Jose LavecchiaMartin Jose Lavecchia
Martin Jose Lavecchia

15 July 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
LHLeandro Martinez Heredia
Leandro Martinez Heredia
PQPatricia Araceli Quispe
Patricia Araceli Quispe
JFJulián Fernández
Julián Fernández
Martin Jose LavecchiaMartin Jose Lavecchia
Martin Jose Lavecchia
Since the early stages of modern medicine, natural products have been a source of inspiration for the development of bioactive compounds. Around half of approved small molecule drugs trace their origins to natural products or their derivatives, highlighting the importance of their correct classification and identification. The information generated by the experimental groups is not usually unified, and is available only in publications or general databases, where the compounds are not linked to their natural sources. To address this need, numerous natural product databases specific to distinct geographic regions have emerged. In this work, we introduce NaturAr, a natural products database dedicated to the cataloging of the rich biodiversity of Argentina. At the time of submission, 228 papers were reviewed, leading to a database of more than 1200 compounds from all across the country. A distinctive quality of this database is its collaborative and open-source framework, which promotes contributions from the research community. NaturAr is freely available online at https://naturar.quimica.unlp.edu.ar.

3 September 2026 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
Juan Diego GuarimataJuan Diego Guarimata
Juan Diego Guarimata
LHLeandro Martinez Heredia
Leandro Martinez Heredia
EMEstefanía Montiel
Estefanía Montiel
PQPatricia Araceli Quispe
Patricia Araceli Quispe
Martin Jose LavecchiaMartin Jose Lavecchia
Martin Jose Lavecchia
Protein kinases are the most intensively targeted protein family for small-molecule drugs, and the large volume of inhibitory-assay data reported for them makes the family particularly well suited to data-driven and machine-learning approaches to drug discovery. This data, however, is scattered across heterogeneous assays, reports and publications, and its reuse for modeling requires substantial curation. Here, we present Kinoteca, a curated database of kinase inhibitory-activity data derived from ChEMBL and accessible through a web interface for browsing, filtering, visualization and download. Kinoteca reconciles the multiple raw independent measurements reported for each combination of compound, kinase and activity type into a single fused activity value, together with a dispersion score based on the mean unsigned error (MUE) that quantifies how consistent the underlying measurements were. The database currently organizes curated data for 585 kinases and arranges them along biologically meaningful groupings such as kinome family, pathway and source organism. Curated activities can be filtered by the physicochemical properties of the assayed molecules or by measurement quality, explored through summary statistics, activity distributions and structural clustering, and exported either as curated or semi-raw data tables or as molecular structure files. These data formats are suitable for the direct training of machine learning models, such as activity prediction models. By delivering reconciled, analysis-ready data with its provenance preserved, Kinoteca aims to lower the barrier to reproducible, data-driven kinase drug discovery.

18 December 2025 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
PQPatricia Araceli Quispe
Patricia Araceli Quispe
DLDaniel Lietha
Daniel Lietha
Ignacio E. LeónIgnacio E. León
Ignacio E. León
Martin Jose LavecchiaMartin Jose Lavecchia
Martin Jose Lavecchia
Focal Adhesion Kinase (FAK) is a key regulator of tumor cell migration and survival, and its persistent overexpression in aggressive cancers has motivated ongoing efforts to identify novel small-molecule inhibitors. Despite this interest, progress in discovering new potent scaffolds has been limited. In this work, we applied a multistep computational workflow followed by experimental testing to refine hit selection and reduce the false positives typically associated with docking. DrugBank and several commercial libraries were screened using Exponential Consensus Ranking (ECR) docking, and molecular dynamics simulations were used to assess pose stability and interaction persistence. A subset of predicted binders was then tested in MG-63 (bone cancer) and MDA-MB-231 (breast cancer) cells using cell viability and wound-healing assays, followed by direct autophosphorylation assays with recombinant FAK. Several repurposed compounds, including clofazimine and tafamidis, produced clear dose-dependent effects on cell migration, although their inhibitory activity in biochemical assays remained weak (IC50 values above 100 μM), far from the potency of the reference inhibitor TAE226. Retrospective analysis of the computational workflow showed that standard MM-GBSA calculations did not correlate with these experimental outcomes. However, incorporating explicit water molecules through the NWAT-MMGBSA approach improved agreement with the biochemical data and helped to rationalize the limited affinity observed experimentally. Taken together, the results underline the relevance of explicit solvation in modeling the FAK active site and suggest that refined solvent-aware protocols may provide more reliable guidance for future screening efforts.

30 August 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
PQPatricia Araceli Quispe
Patricia Araceli Quispe
LHLeandro Martinez Heredia
Leandro Martinez Heredia
Ignacio E. LeónIgnacio E. León
Ignacio E. León
Martin Jose LavecchiaMartin Jose Lavecchia
Martin Jose Lavecchia
Quantitative comparison of ligand-target interaction profiles is often challenging due to subjective interpretations in visual inspection or limitation to predefined interactions in analytical methods. Moreover, traditional analyses tend to overlook the dynamic nature of the interactions, focusing instead on mean energy values. By describing ligand-residue interactions as energy distributions, we account for these dynamics. Assuming a Gaussian distribution, the mean and standard deviation are sampled from molecular dynamics simulations. Using the Sørensen-Dice similarity index, we constructed a metric where the overlap between Gaussian interactions quantifies their similarity. For ligand comparison, the average per-residue similarity is employed. This method allows for post-processing techniques like clustering and dimensionality reduction. We applied it to the focal adhesion kinase (FAK) type II inhibitors targeting the ATP binding site, identifying interaction patterns among the inhibitors.